← Back to Search

Exercise for Alzheimer's Disease (RAATE Trial)

N/A
Recruiting
Led By Robert L Newton, Jr., PhD
Research Sponsored by Pennington Biomedical Research Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Short Physical Performance Battery score >/= 4
Aged 60 years and older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 24 weeks, 52 weeks
Awards & highlights

RAATE Trial Summary

This trial is designed to study the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults, comparing a physical activity program to an active control group.

Who is the study for?
The RAATE trial is for African American adults aged 60 and older who are not currently exercising regularly. Participants must be physically able to exercise, willing to attend group sessions, and have no plans to move during the study. They should not have cognitive impairments that interfere with group interactions or any medical conditions that make regular exercise unsafe.Check my eligibility
What is being tested?
This trial tests if a physical activity program can affect risk factors for Alzheimer's Disease in older African Americans. It compares this program against an active control group, focusing on changes in cognitive function, brain structure and function, as well as physiological parameters like blood pressure and fitness levels.See study design
What are the potential side effects?
Since the intervention involves physical activity tailored for older individuals, potential side effects may include typical exercise-related risks such as muscle strains or sprains. However, participants will be screened to minimize risks of serious injury.

RAATE Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My physical ability score is 4 or higher.
Select...
I am 60 years old or older.

RAATE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 24 weeks, 52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 24 weeks, 52 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in episodic memory
Change in executive function
Secondary outcome measures
APOE genotype
Change in blood pressure
Change in brain structure
+13 more

RAATE Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Physical activity interventionExperimental Treatment1 Intervention
The intervention group will target 150 minutes of moderate to vigorous aerobic physical activity and two days of strength training, consistent with the current physical activity recommendations. Participants will engage in 2 days per week of supervised activity at community facilities. These participants will be requested to engage in an additional 30 minutes of moderate to vigorous aerobic physical activity two days per week at home.
Group II: Active controlActive Control1 Intervention
The active control group will be based on a low-intensity activity program and a healthy aging educational component. The physical activities will include stretching, balance training, flexibility, relaxation, and practicing activities of daily living. The successful aging education component will cover topics including avoiding scams, fall prevention, living wills, and dementia awareness.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Physical activity
2011
Completed Phase 2
~4740

Find a Location

Who is running the clinical trial?

Pennington Biomedical Research CenterLead Sponsor
305 Previous Clinical Trials
181,911 Total Patients Enrolled
National Institute on Aging (NIA)NIH
1,675 Previous Clinical Trials
28,020,760 Total Patients Enrolled
Robert L Newton, Jr., PhDPrincipal InvestigatorPennington Biomedical Research Center
2 Previous Clinical Trials
241 Total Patients Enrolled

Media Library

Physical activity Clinical Trial Eligibility Overview. Trial Name: NCT03890861 — N/A
Alzheimer's Dementia Research Study Groups: Physical activity intervention, Active control
Alzheimer's Dementia Clinical Trial 2023: Physical activity Highlights & Side Effects. Trial Name: NCT03890861 — N/A
Physical activity 2023 Treatment Timeline for Medical Study. Trial Name: NCT03890861 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor open to elderly participants aged 75 and above?

"This clinical trial accepts participants whose ages range from 60 to 85 years old."

Answered by AI

What population can partake in this clinical examination?

"This medical investigation requires 200 individuals aged between 60 and 85 with Alzheimer's disease to participate. Furthermore, they must self-declare as African American; be without any ailments that could endanger them during exercise (e.g., uncontrolled asthma or serious sickle cell disease); not partake in regular physical activity; agree to randomization; join group meetings; have no plans of relocating during the experiment period; achieve a minimum score of 4 on the Short Physical Performance Battery Test, plus demonstrate bodily aptitude for exertion."

Answered by AI

Is enrollment currently open for participation in the experiment?

"Yes, according to the information hosted on clinicaltrials.gov, this medical trial has opened its recruitment of participants since August 9th 2019 and is currently seeking 200 patients from 1 location."

Answered by AI

What goals does this clinical trial seek to accomplish?

"This clinical trial aims to assess the alteration of executive function over a 24 week, 52-week span. Additionally, secondary outcomes monitored include changes in blood pressure (measured using an Omron BP710 automatic cuff), weight (evaluated with a stadiometer to the nearest centimetre) and glucose levels (assessed via conventional assays)."

Answered by AI

What is the upper-limit participant count of this clinical experiment?

"Affirmative. According to clinicaltrials.gov, this ongoing trial was first published on August 9th 2019 and has been revised as of February 15th 2022. The researchers are looking for 200 people to join the study at a single location."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"
Robert L. Newton, Jr. 2019. "Reducing African Americans' Alzheimer's Disease Risk Through Exercise (RAATE)"". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03890861.
~24 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top